These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9515202)

  • 1. Interleukin-6 in multiple myeloma and related plasma cell dyscrasias.
    Treon SP; Anderson KC
    Curr Opin Hematol; 1998 Jan; 5(1):42-8. PubMed ID: 9515202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the biology of multiple myeloma: therapeutic applications.
    Anderson K
    Semin Oncol; 1999 Oct; 26(5 Suppl 13):10-22. PubMed ID: 10528890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma.
    Barillé S; Bataille R; Amiot M
    Eur Cytokine Netw; 2000 Dec; 11(4):546-51. PubMed ID: 11125296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM
    Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
    Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
    Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dehydroepiandrosterone can inhibit the proliferation of myeloma cells and the interleukin-6 production of bone marrow mononuclear cells from patients with myeloma.
    Liu S; Ishikawa H; Li FJ; Ma Z; Otsuyama K; Asaoku H; Abroun S; Zheng X; Tsuyama N; Obata M; Kawano MM
    Cancer Res; 2005 Mar; 65(6):2269-76. PubMed ID: 15781640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
    Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
    Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma.
    Gadó K; Domján G; Hegyesi H; Falus A
    Cell Biol Int; 2000; 24(4):195-209. PubMed ID: 10816321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paraproteinaemias: pathophysiology.
    Samson D
    Schweiz Med Wochenschr; 2000 Nov; 130(44):1643-8. PubMed ID: 11103434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokines and signal transduction.
    Hideshima T; Podar K; Chauhan D; Anderson KC
    Best Pract Res Clin Haematol; 2005; 18(4):509-24. PubMed ID: 16026734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signalling and survival pathways in multiple myeloma.
    Bommert K; Bargou RC; Stühmer T
    Eur J Cancer; 2006 Jul; 42(11):1574-80. PubMed ID: 16797970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Requirement of soluble factors produced by bone marrow stromal cells on the growth of novel established human myeloma cell line.
    Aikawa S; Hatta Y; Tanaka M; Kaneita Y; Yasukawa K; Sawada U; Horie T; Tsuboi I; Aizawa S
    Int J Oncol; 2003 Mar; 22(3):631-7. PubMed ID: 12579318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
    Standal T; Hjorth-Hansen H; Rasmussen T; Dahl IM; Lenhoff S; Brenne AT; Seidel C; Baykov V; Waage A; Børset M; Sundan A; Hjertner O
    Haematologica; 2004 Feb; 89(2):174-82. PubMed ID: 15003892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
    Lin B; Podar K; Gupta D; Tai YT; Li S; Weller E; Hideshima T; Lentzsch S; Davies F; Li C; Weisberg E; Schlossman RL; Richardson PG; Griffin JD; Wood J; Munshi NC; Anderson KC
    Cancer Res; 2002 Sep; 62(17):5019-26. PubMed ID: 12208756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
    Hayashi T; Hideshima T; Nguyen AN; Munoz O; Podar K; Hamasaki M; Ishitsuka K; Yasui H; Richardson P; Chakravarty S; Murphy A; Chauhan D; Higgins LS; Anderson KC
    Clin Cancer Res; 2004 Nov; 10(22):7540-6. PubMed ID: 15569984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
    Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
    Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors.
    Jourdan M; Mahtouk K; Veyrune JL; Couderc G; Fiol G; Redal N; Duperray C; De Vos J; Klein B
    Eur Cytokine Netw; 2005; 16(1):57-64. PubMed ID: 15809207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
    Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
    Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.